Category news

Multi-Organ Tissue Microarray for Pharmaceutical R&D

For decades, the multi-organ tissue microarray (TMA) has served a crucial, albeit passive, role in pharmaceutical Research & Development: the safety net. In the preclinical stages, a novel compound is screened against a TMA containing heart, liver, kidney, lung, and…

Prostate Cancer FFPE Tissue Blocks for Genomic Studies

In the quiet, climate-controlled archives of pathology departments worldwide lie millions of unassuming wax-embedded blocks. These Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks, particularly those from prostate cancer cases, have long been regarded as static relics—diagnostic snapshots preserved for legal and historical…

breast cancer tissue microarray with ER/PR/HER2 status

For decades, the management of breast cancer was guided by a powerful, if simplistic, triad: Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 status. This classification, made possible by techniques like immunohistochemistry on tissue microarrays (TMAs), divided a complex disease…

matched primary and metastatic tissue array

Metastasis is the ultimate villain in the story of cancer. It is the moment a localized rebellion becomes a systemic war, and it is responsible for the vast majority of cancer-related deaths. For years, the process of metastasis remained a…

lung cancer FFPE block with biomarker data

In the quiet, climate-controlled archives of pathology labs worldwide, millions of small, wax-embedded blocks sit in neat rows. To the uninitiated, they are inert, historical artifacts—remnants of a diagnostic process completed long ago. But to the modern oncologist and researcher,…